Starpharma Holdings Limited SPL
ASX · Avustralya · Sağlık Teknolojisi
AUD 0,8050+0,01 (+%1,26)
Piyasa açık· · AUD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa açık· · AUD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
London, United Kingdom--(Newsfile Corp. - September 30, 2026) - Edison issues report on Starpharma (ASX: SPL)Starpharma is a biotechnology company specialised in targeted oncology, underpinned by its proprietary, clinically established dendrimer enhanced product (DEP) platform. The investment case combines two approaches to value creation: retaining more favourable economics through internally developed targeted oncology assets, while partnered programmes broaden DEP's reach, validate the...
Starpharma CEO Cheryl Maley talked with Proactive at the ASX Small and Mid-Cap Conference about its dendrimer technology, oncology treatments and FY26. Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique pro
As Australian shares follow Wall Street into the red, with geopolitical tensions and economic uncertainties casting a shadow over market sentiment, investors are increasingly seeking refuge in more stable sectors like consumer staples. In such volatile times, growth companies with high insider ownership can offer a compelling investment narrative as they often signal strong confidence from those who know the business best.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.